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Purpose: CA-125 has been proposed as a potential marker
for endometrial receptivity in assisted reproduction. This
study was designed to evaluate whether the levels of CA-
125 in the serum of patients undergoing IVF-embryo trans-
fer (ET) is correlated with the outcome.
Methods: Levels of serum CA-125 were measured on the
day before and on the day of human chorionic gonadotropin
(hCG) administration, ovum pickup (OPU), and ET in 74
patients undergoing 100 IVF cycles between January 1994
and March 1995. Patients were treated with a midluteal-
phase gonadotropin-releasing hormone (GnRH) agonist pro-
tocol and follicular-phase human menopausal gonadotropin.
Results: One hundred oocyte retrievals resulted in 91 ETs,
and 22 clinical pregnancies (22%|OPU and 24.2%/ET). The
live-born rate was 21%/OPU and 23.1%/ET. Neither the
CA-125 serum levels nor their increase from the day of hCG
until the day of ET showed any prognostic significance to
the outcome of IVF, and they were not correlated with the
endometrium thickness or the number of oocytes retrieved
or fertilized.
Conclusions: The CA-125 serum levels in conventional IVF
cycles were not correlated with the IVF outcome and yielded
no prognostic information in a GnRH agonist down-regula-
tion protocol.
KEY WORDS: CA-125; in vitro fertilization; endometrium;
receptivity.
INTRODUCTION
Pregnancy outcome after in vitro fertilization (IVF)
depends on many factors, but mainly on the quality
of the embryos and the endometrial receptivity.
CA-125, well-known as a tumor marker for epithe-
lial ovarian cancer (1), is a high molecular weight
glycoprotein that is produced not only by ovarian can-
cer, but also by nonovarian tumors, normal epithelia
of the peritoneum, the endometrium, the fallopian tube,
and the ovary. In some patients undergoing ovarian
hyperstimulation, increased serum levels are detected.
The exact source and amount of production are not
entirely known. Because CA-125 is also produced by
the endometrium, some authors suggest that CA-125
can be used as a marker for endometrial receptivity in
patients undergoing IVF. Its role as a predictor for
pregnancy outcome is controversial (2-4). Therefore,
we sought to evaluate whether CA-125 serum levels
have any predictive prognostic value regarding the
outcome of conventional IVF.
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MATERIALS AND METHODS
Patients and IVF Protocols
Sera from 74 patients who underwent 100 conven-
tional IVF cycles between January 1994 and March
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1995 were analyzed. Fifty-five patients underwent
one cycle, twelve underwent two cycles, and seven
underwent three cycles during that period. Stimula-
tion protocols were identical in all patients: D-Trp6-
gonadotropin-releasing hormone agonist (0.1 mg;
Decapeptyl; Ferring, Duebendorf, Switzerland) was
administered subcutaneously daily from the luteal
phase of the preceding cycle. After the onset of
menses, if transvaginal ultrasound showed no ovarian
cyst and the estradiol (E2) levels were <40 pg/ml,
stimulation was initiated with human menopausal
gonadotropin (hMG) (Pergonal, Serono, Zug, Swit-
zerland, or Humegon, Organon, Switzerland). The
daily doses ranged from 150 to 300 1U per day. D-
Trp was continued until the day of human chorionic
gonadotropin (hCG) administration. On the basis of
E2 levels and the presence of at least two follicles
17 mm or greater in diameter, as monitored by
transvaginal ultrasound, 10,000 IU of hCG (Profasi,
Serono, or Pregnyl, Organon) was given. Thirty-five
to 38 hours later, oocyte pickup (OPU) was performed
under i.v. sedation. Oocytes were aspirated into hepa-
rin-containing flushing medium at 37 °C (Medi-Cult;
Copenhagen, Denmark), cultured in IVF medium
(Medi-Cult) and inseminated with 50,000 to 100,000
motile spermatozoa prepared by Percoll gradient in
the same medium (1 ml). On the following day,
fertilization was assessed microscopically and the
culture medium was replaced; supernumerary pronu-
clear-stage zygotes were frozen. Embryos were
replaced 2 days after oocyte retrieval. One thousand
international units of hCG was given intramuscularly
every other day until the first measurement of hCG
14 to 15 days after embryo transfer (ET). Clinical
pregnancy was defined as a positive heart action in
transvaginal ultrasound 4 to 6 weeks after ET.
Blood was collected 2 and/or 3 days before OPU
(day hCG/hCG-1), on the day of OPU, and on the
day of ET. Care was taken that on the day of OPU,
the blood samples were collected by venipuncture prior
to insertion of the oocyte aspiration needle, to avoid
any possible spilling of follicular CA-125 into the
circulation. Serum was obtained by immediate centrif-
ugation after coagulation and stored at — 30°C until
CA-125 and hormone analyses were performed in
batches. Blood was not taken on all 4 days for all
the cycles.
Measurement of Serum Levels
Serum concentrations of CA-125 were determined
by CA-125-11 enzyme immunoassay (ElA), based on
a double-antibody method using both the OC 125 and
the M 11 antibody. The tests were run in batches on
an automatic Cobas Core immunoanalyzer (F. Hoff-
man-La Roche, Switzerland). The sensitivity of the
test was 1.0 lU/ml. Intra- and inter-assay coefficients
of variance at the low end of the standard assay range
had been determined in a trial involving four centers
and were 4.4% (number of repetitions = 21) and 5.1%,
respectively, for a CA-125 concentration of 17.2 lU/ml.
Serum levels of E2 were determined by dissociation-
enhanced lanthanide immunofluorometric assay (Del-
fia; Wallac, Finland) according to the manufacturer's
instructions.
Progesterone was measured by radioimmunoassay
using a coated tube kit (Coat-a-count; DPC, Los
Angeles, CA). Due to the high serum progesterone
levels encountered after ovarian hyperstimulation, all
samples obtained on the day of ET were diluted 1:10
with zero diluent (DPC) prior to assay.
Statistical Analysis
Comparisons of the different parameters between
the pregnant and the nonpregnant groups were made
using the nonparametric Mann-Whitney test for two-
tailed P values, because the data were not normally
distributed. Only cycles with ET were included in
that analysis. A P value < 0.05 was considered
significant. Regression was used to detect any correla-
tion between CA-125 levels and the number of
oocytes retrieved, fertilization, the endometrial thick-
ness, the embryo score, and the E2 and progesterone
levels, including all cycles. Statistical calculations
were performed using the StatView SE & Graphics
package for Macintosh.
RESULTS
This study included 74 patients undergoing a total
of 100 oocyte retrievals, resulting in 91 ETs and 22
clinical pregnancies (22% per OPU and 24.2% per
ET). Twenty-one patients delivered live-born infants,
and one patient had a pregnancy loss at 8 weeks of
gestation. The take-home baby rate was 21% per OPU
and 23.1% per ET.
The patient characteristics are summarized in Table
I. The patients' ages ranged from 25 to 41 years, with
a median of 34 years. There were no statistically signi-
ficant differences in the patient age or attempt number,
number of follicles retrieved, fertilization rate, cumula-
tive embryo score (sum of blastomere numbers times
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the quality factor, ranging from 1 = least to 4 =
best, totaled for all transferred embryos), or number
of embryos transferred. The endometrium thickness
was higher in the pregnancy group (P = 0.048). Endo-
metriosis was observed in 19 cycles (18 patients); 3
of them resulted in ongoing pregnancies.
Table II summarizes the levels of progesterone and
E2, which were not of prognostic value.
Table III shows the CA-125 serum levels on the day
before and at hCG administration, oocyte retrieval,
and ET, respectively. The differences in CA-125 levels
between the pregnant and the nonpregnant groups were
found to be nonsignificant. No correlation existed
between serum CA-125 levels and endometrial thick-
ness, number of retrieved and number of fertilized
oocytes, cumulative embryo score, and serum estradiol
and progesterone concentrations, respectively. The
presence or absence of endometriosis did not have a
statistically significant effect on the observed CA-125
levels on any of the 4 days investigated, whether the
whole study group was taken into account or the con-
ceptual and nonconceptual cycles were analyzed sepa-
rately (data not shown).
CA-125 increased significantly from the day of hCG
administration unt i l the day of ET, but the increase did
not differ significantly between the pregnant (increase,
1.59-fold) and the nonpregnant (1.83-fold) groups.
DISCUSSION
CA-125 has been detected in the follicular fluid of
patients undergoing IVF, as well as in their serum.
Several groups, however, have postulated that the
determination of CA-125 in the follicular fluid has no
prognostic value with respect to the outcome (2, 4-7).
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Table II. Serum Steroid Hormone Levels on Days hCG-1, hCG, OPU, and ET
Pregnant
E2 (pg/ml)a
Day hCG
Day hCG
Day OPU
Day ET
Progesterone
Day hCG
Day hCG
Day OPU
Day ET
- 1
n
15
10
21
20
Median
2,138.3
2,358.9
953.4
889.4
Range
563.8-5,066.1
487.6-7,518.2
264.2-2,495.2
315.9-2,132.6
n
34
45
58
66
Nonpregnant
Median
1,648.0
2,299.1
1,084.1
727.3
Range
359.6-4,528.8
795.8-6,619.3
171.6-3,050.8
73.5-2,590.5
P value
0.17(ns) c
0.83 (ns)
0.85 (ns)
0. 1 8 (ns)
(pg/ml)b
- 1 15
10
20
21
911.9
880.5
8,569.0
78,709.3
471.7-1,446.5
566.0-4,591.8
4,150.8-45,942.6
5,377.5-186,663.45
37
42
58
66
723.3
1,037.7
7,688.5
58,914.1
251.5-2,484.2
408.8-3,836.4
2,955.9-40,282.2
5,477.2-343,799.1
0.13 (ns)
0.47 (ns)
0.26 (ns)
0.34 (ns)
" Conversion factor to SI 3.671.
b
 Conversion factor to SI 3. 1 80.
c
 ns = not signicant.
Table I. Patient Synopsis
Pregnant
No. of patients
Age (yr)
No. of attempts
No. of follicles retrieved
No. of fertilized oocytes
Fertilization rate (%)
Embryos/transfer
Cumulative embryo score
Endometrium thickness (mm)
Median
22
(21 delivered)
34
1 (mean, 2.0)
7
5
68.7
3 (mean, 2.6)
34
12.4
(mean, 12.0)
Range
26-38
1-7
4-28
1-16
10-100
1-3
6-57
4-15.1
Nonpregnant
Median
69
34
1 (mean, 1.8)
8
5
75.0
3 (mean, 2.8)
32
10.5
(mean, 10.8)
Range
25-41
1-5
2-33
1-24
9.5-100
1-4
2-57
4-18
P value
0.44 (ns)a
0.88 (ns)
0.86 (ns)
0.96 (ns)
0.41 (ns)
0.31 (ns)
0.67 (ns)
0.048
a
 ns = not significant.
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On the other hand, C A-125 is produced by the endome-
trial epithelium, and therefore, an endocrine or a para-
crine function could be possible. The role of CA-125 as
a marker for uterine receptivity has been controversial
(2-4). These two aspects prompted us to investigate
the usefulness of secreted (i.e., present in the serum)
CA-125 as a potential indicator for the possible occur-
rence of a pregnancy in IVF treatment.
Our study shows that there was no correlation
between the CA-125 levels on the 4 days on which
blood samples were taken and the pregnancy outcome.
Serum concentrations of CA-125 showed great vari-
ability within each patient group, both pregnancy and
nonpregnancy outcomes. Although the endometrium
was slightly thicker in the pregnancy group, there was
no correlation between endometrial thickness and CA-
125 levels—this would have been expected to some
extent in the case of a significant contribution of the
endometrium to CA-125 production and release. The
lack of correlation argues against a quantitative rela-
tionship, however, not against a qualitative (physio-
logic) one. There was no correlation between CA-
125 levels and ovarian steroid hormone concentrations
found in the serum. These results may be explained
by the multiple-site production of CA-125, which is
not restricted to the endometrium. In patients without
cancer the fallopian tube, endocervix, peritoneum,
pleura, and pericardium have been found to be sources
of production.
The exact location and amount of CA-125 produced
in the female genital tract during ovarian hyperstimula-
tion remain unclear. Sources of production are the
ovary (7), endometrium (8), and peritoneum (9). In
women undergoing ovarian superovulation before and
after vaginal hysterectomy, the differences in luteal
CA-125 levels were similar (10), suggesting major
extraendometrial production of CA-125, mainly in the
ovary and/or peritoneum. Ozaksit et al. (5), studying
patients either with a normal cycle, stimulated for intra-
uterine insemination, or undergoing IVF, found
increased CA-125 levels only in the luteal phase of
patients with ovarian hyperstimulation syndrome, sug-
gesting peritoneal rather than significant endometrial
or corpus luteum production of CA-125. Levels of
CA-125 can be 15 to 50 times higher in pregnant
patients with ovarian hyperstimulation syndrome and
in patients with ectopic pregnancy with peritoneal irri-
tation (9,11), suggesting that high CA-125 levels in
stimulated patients might be due to not only an ovarian
and endometrial, but also a peritoneal, contribution.
We believe that our results are due to the fact that
CA-125 production is not restricted to the endome-
trium. Our results are comparable to those of Phocas
et al. (2), who found no correlation between serum
or follicular fluid CA-125 and estradiol, testosterone,
oocyte quality, fertilization, and pregnancy rate. On
the other hand, a recent study showed elevated serum
C A-125 concentrations on the day of hCG administra-
tion in conceptual cycles (3). The sensitivity was 72%,
the specificity 97%, and the positive predictive value
for pregnancy 95% in patients with CA-125 levels
greater than 16 IU/ml on the day of hCG administra-
tion. The positive significance of CA-125 was present,
but less strong, on the day before hCG. In that particu-
lar study, CA-125 was not measured on the day of
oocyte retrieval or ET.
In contrast, Chryssikopoulos et al. (4) found
increased CA-125 serum concentrations in the preg-
nancy group only on the day of retrieval, and not on
the day of hCG administration and ET. The increase
in CA-125 from the day of hCG until the day of oocyte
retrieval was higher in the pregnancy group.
The different results of the four reports are difficult
to explain. The stimulation protocols were different:
three groups (Refs. 2 and 3 and this study) used a
gonadotropin releasing hormone (GnRH) agonist
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Table III. Serum CA-125 Concentrations and Rates of Increase
Pregnant
CA-125(IU/ml)
Day hCG - 1
Day hCG
Day OPU
Day ET
Day OPU:hCG
Day ET:hCG
Day ET:OPU
n
15
10
20
21
10
9
19
Median
11.7
15.9
14.25
21.5
.98
1.45
1.22
Range
2.8-168.4
7.6-137.7
7.3-172.1
8.4-200.9
0.79-1.34
0.57-3.21
0.7-2.71
n
34
45
61
66
38
43
58
Nonpregnant
Median
13.4
12.2
16.7
20.7
1.12
1.64
1.36
Range
3.2-90.1
3.3-30.5
4.3-97.2
6.2-76.2
0.68-2.02
0.70-5.03
0.64-3.27
P value
0.21 (ns)a
0.13 (ns)
0.93 (ns)
0.50 (ns)
0.09 (ns)
0.39 (ns)
0.92 (ns)
a
 ns = not significant.
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down-regulation protocol, while Chryssikopoulos et
al. (4) used a short GnRH protocol. Because the half-
life of CA-125 in the serum is 4.5 days (12), ovarian
down-regulation will have a different effect than the
flare protocol. Such stimulation-induced differences in
the control of CA-125 production and release might
be stronger than the variation in endometrial glandular
function, which in turn has an effect on the outcome
(pregnancy or not).
Other factors, such as the number of embryos trans-
ferred and the different CA-125 assay protocols used
by various groups, might also provide an explanation
for the conflicting results. Our group used the Cobas
Core (Roche) method, Chryssikopoulos et al. (4) a
RIA kit from Abbott Laboratories, and Miller et al. (3)
an immunoradiometric assay from Centocor (Malvern,
PA). For this reason, the different studies in the litera-
ture cannot be directly compared, because the afore-
mentioned methods show considerable differences in
the antigen determinant specificity and the type of
standard used in the respective kits. The assay used
in our study used CA-125 antibodies OC 125 and
Ml 1 and has shown a good reproducibility in the low
ranges(<20 lU/ml) (13).
The findings presented in this study, however, relate
to the CA-125 assay we used and may not be applicable
to other assays. The sensitivity, specificity, and positive
predictive value will also depend on the prevalence of
the condition, in this case pregnancies, for the days
sampled, which was different among the studies. It
might also be argued that within a larger population,
the difference might become statistically significant.
However, CA-125 showes a wide range even in healthy
women, with values ranging from less than 5 to greater
than 60 U/L (13). Because of the great variance and
overlapping values in the pregnancy and nonpregnancy
groups, in our population, as well as the controversial
reports in the literature, determination of CA-125 is
currently not performed routinely as an IVF outcome
prognosticator at our clinic. The study of a very large
patient population, treated with identical ovarian stim-
ulation protocols and using identical CA-125 assays,
might, however, be warranted.
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